R&G PharmaStudies Co., Ltd. (SHE:301333)
China flag China · Delayed Price · Currency is CNY
58.71
+0.91 (1.57%)
Nov 5, 2026, 4:00 PM EST

R&G PharmaStudies Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Net Income
116.51136.9140.22162.53113.4599.24
Depreciation & Amortization
12.9220.3336.3134.5719.0336.05
Other Amortization
24.4717.061.42.1917.41.59
Loss (Gain) From Sale of Assets
0.010.010.070.020.020.02
Asset Writedown & Restructuring Costs
---0--
Loss (Gain) From Sale of Investments
-21.1-21.1-24.95-27.44-9.14-2.6
Provision & Write-off of Bad Debts
5.195.193.364.863.577.54
Other Operating Activities
24.918.284.960.23-3.563.29
Change in Accounts Receivable
-22.35-49.72-54.95-20.08-42.52-58.34
Change in Inventory
6.226.22-4.231.75-9.74-14.6
Change in Accounts Payable
0.226.8852.1921.6642.5543.5
Change in Other Net Operating Assets
-34.7-13.98-0.0213.270.220.36
Operating Cash Flow
110.45114.2154.76192.56130.47114.57
Operating Cash Flow Growth
31.81%-26.21%-19.63%47.60%13.87%159.80%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Capital Expenditures
-15.99-19.28-19.98-19.88-20.83-38.28
Sale of Property, Plant & Equipment
0.070.010.010.020.150.09
Cash Acquisitions
-24-24-21.31---
Investment in Securities
533.0841.5-26-710--
Other Investing Activities
12.4920.8722.9525.059.142.6
Investing Cash Flow
505.6519.11-44.33-704.8-11.54-35.59

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Short-Term Debt Issued
--54.79---
Total Debt Issued
--54.79---
Long-Term Debt Repaid
--69.01-14.36-12.74-11.5-9.94
Lease Payments
-13.87-13.87-14.36-12.74-11.5-9.94
Net Debt Issued (Repaid)
-13.87-69.0140.43-12.74-11.5-9.94
Issuance of Common Stock
11.0115.18-1,114-
Repurchase of Common Stock
---56.09---
Common Dividends Paid
-21.76-11.78-28.38-5.82--
Other Financing Activities
-49.910.75-19.87--66.99-
Financing Cash Flow
-84.52-69.03-48.74-18.561,036-9.94

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Foreign Exchange Rate Adjustments
-9.91-3.721.761.15.44-1.27
Net Cash Flow
521.6660.5663.44-529.691,16067.77

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
94.4694.93134.78172.68109.6476.29
Free Cash Flow Growth
58.05%-29.57%-21.95%57.50%43.71%309.66%
Free Cash Flow Margin
9.87%11.15%18.12%23.94%17.20%12.54%
Free Cash Flow Per Share
0.990.991.411.801.331.06
Levered Free Cash Flow
-0.7964.94116.07133.1980.644.54
Unlevered Free Cash Flow
-0.466.73118.22133.5681.0244.9
Free Cash Flow After Leases
80.5981.06120.42159.9498.1466.35

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash Income Tax Paid
55.0858.3452.1555.140.945.16
Change in Working Capital
-52.47-52.47-6.6215.6-10.3-30.55